Nyxoah SA
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 9, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 14, 2026 | During market hours | $5.70M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | $1.30M | $-463.00 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | $800.00K | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 9, 2024 | During market hours | $1.80M | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 9, 2023 | During market hours | $1.10M | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 22, 2023 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 8, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 8, 2022 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 24, 2022 | During market hours | – | – | – |
Company guidance
Outlook given with results on Jan 14, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| U.S. net revenue | first quarter of 2026 | 25% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Nyxoah filed with the SEC
Appoints Liam Kelly as Chief Executive Officer
EX-99.1 to Form 6-K
Nyxoah Announces Chief Financial Officer Transition
EX-99.1 to Form 6-K
Publication relating to transparency notifications
EX-99.1 to Form 6-K
Information on the total number of voting rights and shares
EX-99.2 to Form 6-K
Nyxoah Announces Preliminary Results for the Second Quarter
EX-99.3 to Form 6-K
Nyxoah Receives $15 Million from the European
EX-99.1 to Form 6-K
Publication relating to transparency notifications
EX-99.3 to Form 6-K
Information on the total number of
EX-99.1 to Form 6-K
Nyxoah Announces Pricing of $95 Million
EX-99.2 to Form 6-K
Rue Edouard Belin 12, 1435 Mont-Saint-Guibert,
EX-99.1 to Form 6-K
Nyxoah Reports First Quarter 2026 Financial
EX-99.2 to Form 6-K
FDA PMA APPROVAL AND US COMMERCIALIZATION
EX-99.3 to Form 6-K
Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
EX-99.1 to Form 6-K
Information on the total number of voting rights and shares
EX-99.2 to Form 6-K
Publication relating to transparency notifications
EX-99.3 to Form 6-K
Nyxoah Invests In Further Expanding Its Belgian
EX-99.1 to Form 6-K
Nyxoah Announces Preliminary Results for the
EX-99.1 to Form 6-K
Publication relating to transparency notification
EX-99.2 to Form 6-K
Nyxoah Announces Commercial Launch of Genio® Breakthrough
EX-99.1 to Form 6-K
Nyxoah Announces Issuance of First
EX-99.2 to Form 6-K
Publication relating to transparency notifications
EX-99.1 to Form 6-K
Provides Update on Expanded Middle East Presence
EX-99.1 to Form 6-K
Nyxoah Announces Proposed Offering of Ordinary
EX-99.1 to Form 6-K
Nyxoah Announces Pricing of Offering
EX-99.2 to Form 6-K
Nyxoah Files Patent Infringement Lawsuit Against
EX-99.1 to Form 6-K
Nyxoah Reports Second Quarter Financial and Operating Results
EX-99.1 to Form 6-K
Nyxoah Receives Approval from FDA for Genio®
EX-99.1 to Form 6-K
Nyxoah Announces Preliminary Results for the
EX-99.2 to Form 6-K
Data Published in the Journal of Clinical Sleep Medicine
EX-99.1 to Form 6-K
Information on the total number of voting rights
EX-99.1 to Form 6-K
Rue Edouard Belin 12, 1435 Mont-Saint-Guibert,
EX-99.1 to Form 6-K
Publication relating to transparency notifications
EX-99.1 to Form 6-K
Information on the total number of voting rights and shares
EX-99.1 to Form 6-K